Illumina (ILMN -7.88%), a global leader in DNA sequencing and genomics, released its second quarter results on July 31, 2025, for the fiscal 2025 period. The results were notable for beating analyst expectations on both non-GAAP EPS and GAAP revenue. Non-GAAP earnings per share reached $1.19, compared to the $1.01 non-GAAP consensus. Revenue (GAAP) landed at $1.06 billion, just ahead of the $1.05 billion estimate—though down 3% from the prior year. Management also provided a modestly improved full-year outl ...

Illumina (ILMN) Q2 2025 Earnings Call July 31, 2025 04:30 PM ET Company ParticipantsBrian Blanchett - VP - Finance & Treasurer, Interim Head of Investor RelationsJacob Thaysen - CEO & DirectorAnkur Dhingra - CFOVijay Kumar - Senior MDSubbu Nambi - Managing DirectorPuneet Souda - Senior MD - Life Science Tools & DiagnosticsDoug Schenkel - MD - Life Science Tools & DiagnosticsTycho Peterson - MD - Global EquitiesDan Arias - Managing DirectorConference Call ParticipantsEve Burstein - US Life Science Tools and ...